Abstract
Calcium carbonate is widely used as an oral phosphorus binder to control hyperphosphatemia in children on maintenance hemodialysis. Intestinal calcium absorption may induce hypercalcemia, particularly if calcitriol is given simultaneously. In adults, calcium acetate binds phosphorus more effectively than calcium carbonate, while reducing the frequency of hypercalcemic events. We therefore compared calcium acetate with calcium carbonate in nine pediatric patients on long-term maintenance hemodialysis. Following a 1-week withdrawal of phosphorus binders, calcium carbonate was administered for 7 weeks; after a second withdrawal, calcium acetate was given for another 7 weeks. All patients received calcitriol regularly. Both agents lowered the serum phosphorus concentration significantly (calcium carbonate 5.7±1.4 vs. 7.7±2.1 mg/dl, P<0.005; calcium acetate 5.8±1.4 vs. 7.8±2.0 mg/dl, P<0.005). Significantly less elementary calcium was ingested with calcium acetate than with calcium carbonate: 750 (375–1,500) vs. 1,200 (0–3,000) mg calcium/day, P<0.0001. With calcium carbonate serum calcium increased significantly. The number of episodes of hyperphosphatemia or hypercalcemia did not differ between treatments. Intact plasma parathyroid hormone (PTH) decreased significantly with both phosphate binders, and serum 25-hydroxyvitamin D3 increased. There was a close relationship between serum phosphorus and PTH in prepubertal but not in pubertal patients. We conclude that hyperphosphatemia can be controlled effectively by both calcium acetate and calcium carbonate in pediatric hemodialysis patients. The oral load of elementary calcium is reduced significantly by binding phosphorus with calcium acetate instead of calcium carbonate; nevertheless, hypercalcemic episodes remain equally frequent with both phosphate binders.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lopez-Hilker S, Galceran T, Chan YL, Rapp RN, Martin KJ, Slatopolsky E (1986) Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 78:1079–1102
Holick MF (1987) Vitamin D and the kidney. Kidney Int 32:912–929
Bricker NS, Slatopolsky E, Reiss E, Avioli LV (1969) Calcium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med 123:543–553
Bricker NS (1972) On the pathogenesis of the uremic state: an exposition of the “trade- off-hypothesis”. N Engl J Med 286:1093–1099
Chesney RW, Avioli LV (1992) Childhood renal osteodystrophy. In: Edelmann CM Jr (ed) Pediatric kidney disease, 2nd edn. Little Brown, Boston, pp 647–684
Schärer K, Gilli G (1992) Growth retardation in kidney disease. In: Edelmann CM Jr (ed) Pediatric kidney disease, 2nd edn. Little Brown, Boston, pp 593–607
Salusky IB, Coburn JW, Foley J, Nelson P, Fine AR (1985) Calcium carbonate as a phosphate binder in children on dialysis (abstract). Kidney Int 27:185
Alon U, Davidai G, Bentur L, Berant M, Better OS (1986) Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure. Miner Electrolyte Metab 12:320–325
Andreoli SP, Dunson JW, Bergstein JM (1987) Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 9:206–210
Clark AG, Oner A, Ward G, Turner C, Rigden SP, Haycock GB, Chantler C (1989) Safety and efficacy of calcium carbonate in children with chronic renal failure. Nephrol Dial Transplant 4:539–544
Meric F, Yap P, Bia MJ (1990) Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 16:459–464
Mai ML, Emmett MS, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS (1989) Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690–695
Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS (1989) Reduction of dietary phosphorus absorption by phosphorus binders: a theoretical, in vitro, and in vivo study. J Clin Invest 83:66–73
Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J (1986) Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157–161
Ginsburg D, Kaplan E, Katz A (1973) Hypercalcemia after oral calcium-carbonate therapy in dialysis patients on chronic hemodialysis. Lancet I:1271–1275
Gonella M, Culabrese G, Vagelli G, Pratesi G, Lamon S, Talarico S (1985) Effects of high CaCO3 supplements on serum calcium and phosphorus in patients on regular hemodilaysis treatment. Clin Nephrol 24:147–150
Querfeld U, Salusky IB, Fine RN (1988) Treatment of severe hypercalcemia with peritoneal dialysis in an infant with end-stage renal disease. Pediatr Nephrol 2:323–325
Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS (1989) Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 320:1110–1113
Morinière P, Djerad M, Boudailliez B, El Esper N, Boitte F, Westeel PF, Compagnon M, Brazier M, Achard JM, Fournier A (1992) Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Nephron 60:6–11
Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, Von Herrath D (1991) The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 6:170–175
Caravaca F, Santos I, Cubero JJ, Esparrago JF, Arrobas M, Pizarro JL, Robles R, Sanchez-Casado E (1992) Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 60:423–427
Hess B, Binswanger U (1990) Long-term administration of calcium acetate efficiently controls severe hyperphosphataemia in haemodialysis patients. Nephrol Dial Transplant 5:630–632
Schaefer K, Liebke C, Von Herrath D (1990) Calcium acetate: new hope in the treatment of hyperphosphatemia? Semin Dial 3:65–66
Ben Hamida F, El Esper I, Compagnon M, Morinière P, Fournier A (1993) Long-term (6 months) cross-over comparision of calcium acetate with calcium carbonate as phosphate binder. Nephron 63:258–262
Coburn JW, Salusky IB (1989) Control of serum phosphorus in uremia. N Engl J Med 320:1140–1142
Delmez JA, Slatopolsky E (1992) Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19:303–317
Pflanz S, Henderson IS, McElduff N, Jones MC (1994) Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant 9:1121–1124
Ring T, Nielsen C, Paulin Andersen S, Behrens JK, Sodemann B, Kornerup HJ (1993) Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study. Nephrol Dial Transplant 8:341–346
Almirall J, Veciana L, Llibre J (1994) Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. Am J Nephrol 14:192–196
Tanner JM (1962) Growth at adolescence, 2nd edn. Blackwell, Oxford
Bothe V, Schmidt-Gayk H (1990) Competitive protein-binding assay for the diagnosis of hyper- and hypovitaminosis D. In: Schmidt-Gayk H, Armbruster FP, Bouillon R (eds) Calcium regulating hormones, vitamin D metabolites, and cyclic AMP. Springer, Berlin Heidelberg New York, pp 258–279
Hruska KA, Teitelbaum SL (1995) Renal osteodystrophy. N Engl J Med 333:166–174
Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E (1989) Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. J Clin Invest 83:1349–1355
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wallot, M., Bonzel, KE., Winter, A. et al. Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol 10, 625–630 (1996). https://doi.org/10.1007/s004670050175
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s004670050175